{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:34:53Z","timestamp":1788478493216,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.yebeh.2022.109066","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T22:08:06Z","timestamp":1672870086000},"page":"109066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Why ketamine"],"prefix":"10.1016","volume":"141","author":[{"given":"Lisa","family":"Coles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Bleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Elm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Zehtabchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Shinnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Silbergleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.109066_b0005","doi-asserted-by":"crossref","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2022.109066_b0010","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus - Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0015","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.109066_b0025","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.yebeh.2022.109066_b0030","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.109066_b0035","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.1212\/WNL.0000000000010611","article-title":"Ketamine to treat super-refractory status epilepticus","volume":"95","author":"Alkhachroum","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.109066_b0040","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/epi.12247","article-title":"Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study","volume":"54","author":"Gaspard","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0045","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/epi.14676","article-title":"Starting ketamine for neuroprotection earlier than its current use as an anesthetic\/antiepileptic drug late in refractory status epilepticus","volume":"60","author":"Fujikawa","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0050","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajem.2007.12.005","article-title":"Adverse events associated with ketamine for procedural sedation in adults","volume":"26","author":"Strayer","year":"2008","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa002141","article-title":"A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus","volume":"345","author":"Alldredge","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus","volume":"366","author":"Silbergleit","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1528-1157.1995.tb00979.x","article-title":"Neuroprotective Effect of Ketamine Administered After Status Epilepticus Onset","volume":"36","author":"Fujikawa","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0070","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(06)70374-X","article-title":"Status epilepticus: Pathophysiology and management in adults","volume":"5","author":"Chen","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.109066_b0075","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archneurol.2010.169","article-title":"Frequency and Prognosis of Convulsive Status Epilepticus of Different Causes: A Systematic Review","volume":"67","author":"Neligan","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.109066_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1157.1994.tb02908.x","article-title":"Determinants of Mortality in Status Epilepticus","author":"Towne","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0085","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1212\/WNL.0b013e3182759766","article-title":"Acute EEG findings in children with febrile status epilepticus: Results of the FEBSTAT study","volume":"79","author":"Nordli","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.109066_b0090","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.0b013e318266fcc5","article-title":"MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study","volume":"79","author":"Shinnar","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.109066_b0095","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ana.24081","article-title":"Hippocampal sclerosis after febrile status epilepticus: The FEBSTAT study","volume":"75","author":"Lewis","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2022.109066_b0100","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.17-19-07532.1997","article-title":"Rapid seizure-induced reduction of benzodiazepine and Zn2+sensitivity of hippocampal dentate granule cell GABA(A) receptors","volume":"17","author":"Kapur","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2022.109066_b0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00004691-199512040-00004","article-title":"Pathophysiology of Status Epilepticus","volume":"12","author":"Fountain","year":"1995","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2022.109066_b0110","first-page":"410","article-title":"Association of time to treatment with short-term outcomes for pediatric patients with refractory convulsive status epilepticus","volume":"75","author":"Ga\u00ednza-Lein","year":"2018","journal-title":"J Am Med Assoc Neurol"},{"key":"10.1016\/j.yebeh.2022.109066_b0115","first-page":"15","article-title":"Targeting NMDA Receptor Complex in Management of Epilepsy","author":"Sivakumar","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.yebeh.2022.109066_b0120","first-page":"5","article-title":"NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures","author":"Kapur","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.109066_b0125","first-page":"42","article-title":"Ketamine controls prolonged status epilepticus","author":"Borris","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.109066_b0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(99)00238-4","article-title":"N-Methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat","volume":"265","author":"Mazarati","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.yebeh.2022.109066_b0135","first-page":"59","article-title":"A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus","author":"Yen","year":"2004","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.109066_b0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1528-1167.2007.01384.x","article-title":"A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation","volume":"49","author":"Martin","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0145","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/epi.13480","article-title":"Midazolam\u2013ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits","volume":"57","author":"Niquet","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/epi4.12270","article-title":"Role of NMDA receptors in the pathophysiology and treatment of status epilepticus","volume":"3","author":"Kapur","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2022.109066_b0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.nbd.2012.12.015","article-title":"Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus","volume":"54","author":"Naylor","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.yebeh.2022.109066_b0160","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1523\/JNEUROSCI.4346-07.2008","article-title":"Deficits in phosphorylation of GABAA receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus","volume":"28","author":"Terunuma","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2022.109066_b0165","first-page":"48","article-title":"GABA<inf>A<\/inf> receptor internalization during seizures","author":"Goodkin","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0170","first-page":"28","article-title":"Subunit-specific trafficking of GABAA receptors during status epilepticus","author":"Goodkin","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2022.109066_b0175","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1523\/JNEUROSCI.4944-04.2005","article-title":"Trafficking of GABAA receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus","volume":"25","author":"Naylor","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2022.109066_b0180","first-page":"72","article-title":"Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus","author":"Rajasekaran","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2022.109066_b0185","first-page":"103","article-title":"Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neurons during status epilepticus","author":"Joshi","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2022.109066_b0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.yebeh.2005.08.003","article-title":"Prolonged seizures and cellular injury: understanding the connection","volume":"7","author":"Fujikawa","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.109066_b0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ana.10085","article-title":"Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus","volume":"51","author":"Prasad","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2022.109066_b0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0006-8993(97)01285-7","article-title":"NMDA receptor activation during status epilepticus is required for the development of epilepsy","volume":"782","author":"Rice","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.yebeh.2022.109066_b0205","first-page":"84","article-title":"N-Methyl-D-Aspartic acid receptor activation downregulates expression of \u03b4 subunit-containing GABA<inf>A<\/inf> receptors in cultured hippocampal neuronss","author":"Joshi","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.yebeh.2022.109066_b0210","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/epi.13660","article-title":"Neurosteroid-sensitive \u03b4-GABAA receptors: A role in epileptogenesis?","volume":"58","author":"Joshi","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109066_b0215","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1553-2712.1998.tb02773.x","article-title":"Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases","volume":"5","author":"Green","year":"1998","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0220","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1553-2712.2000.tb01076.x","article-title":"Ketamine in Adults What Emergency Physicians Need to Know about Patient Selection and Emergence Reactions","volume":"7","author":"Green","year":"2000","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.annemergmed.2010.11.030","article-title":"Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update","volume":"57","author":"Green","year":"2011","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0230","first-page":"54","article-title":"Predictors of emesis and recovery agitation with emergency department ketamine sedation: an individual-patient data meta-analysis of 8,282 children","author":"Green","year":"2009","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0235","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PCC.0000000000000920","article-title":"Procedural Sedation Outside of the Operating Room Using Ketamine in 22,645 Children: A Report From the Pediatric Sedation Research Consortium","volume":"17","author":"Grunwell","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.yebeh.2022.109066_b0240","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/phar.2243","article-title":"Assessment of Ketamine Adult Anesthetic Doses in Pediatrics Using Pharmacokinetic Modeling and Simulations","volume":"39","author":"Elkomy","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2022.109066_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijso.2020.12.009","article-title":"Operations supported by ketamine anesthesia in resource-limited settings: Surgeons\u2019 perceptions and recommendations \u2013 Qualitative Study","volume":"29","author":"Makin","year":"2021","journal-title":"Int J Surg Open"},{"key":"10.1016\/j.yebeh.2022.109066_b0250","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00000542-198611000-00007","article-title":"Ventilatory pattern and chest wall mechanics during ketamine anesthesia in humans","volume":"65","author":"Mankikian","year":"1986","journal-title":"Anesthesiology"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022005157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022005157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:50:18Z","timestamp":1761504618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022005157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":50,"alternative-id":["S1525505022005157"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.109066","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why ketamine","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.109066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109066"}}